Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 6/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570331 | 0.84 | SGMS2 (0.40) | SGMS2ALDH1A1LMNAKCNJ11CYP2C19 | |
| SCHEMBL15569253 | 0.84 | SGMS2 (0.40) | SGMS2ALDH1A1LMNAKCNJ11CYP2C19 | |
| SCHEMBL15569622 | 0.78 | KCNJ11 (0.39) | SGMS2ALDH1A1KCNJ11KDM4ECSF1R | |
| SCHEMBL15569179 | 0.78 | CYP11B1 (0.39) | SGMS2KCNJ11SLC22A12 | |
| SCHEMBL15569620 | 0.78 | KCNJ11 (0.40) | SGMS2ALDH1A1HPGDKCNJ11CYP2C19 | |
| SCHEMBL15570126 | 0.77 | SGMS2 (0.38) | SGMS2ALDH1A1LMNASLC22A12KDM4E | |
| SCHEMBL17092619 | 0.76 | CCNC (0.40) | HPGDHSD17B10CYP2C19CSF1RVDR | |
| SCHEMBL17092629 | 0.76 | CCNC (0.40) | HPGDHSD17B10CYP2C19CSF1RVDR | |
| SCHEMBL17092618 | 0.76 | CCNC (0.40) | HPGDHSD17B10CYP2C19CSF1RVDR | |
| SCHEMBL15569693 | 0.74 | ROCK2 (0.40) | ALDH1A1HSD17B10KDM4ECSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2888232-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014029726-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | TP53, RB1, HCCS | SGMS2 2503/4885ALDH1A1 401/4885HPGD 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.